Global Hairy Cell Leukemia Therapeutics Market 2019-2023
SKU ID : TNV-14588444 | Publishing Date : 30-Jul-2019 | No. of pages : 129
Detailed TOC of Global Hairy Cell Leukemia Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
Chemotherapy - Market size and forecast 2018-2023
Targeted therapy - Market size and forecast 2018-2023
Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Increasing research grants for blood cancers
Advent of novel therapies
Special drug designations
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
AstraZeneca Plc
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Mylan NV
Pfizer Inc.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 22: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Targeted therapy - Year-over-year growth 2019-2023 (%)
Exhibit 24: Patient assistance programs
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Proportion of geriatric population in Asia 2009 and 2018
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Growth in geriatric population 2014-2018 (%)
Exhibit 45: Side effects of chemotherapy drugs used for treatment of hairy cell leukemia
Exhibit 46: Impact of drivers and challenges
Exhibit 47: Drug designations
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: AstraZeneca Plc - Vendor overview
Exhibit 54: AstraZeneca Plc - Business segments
Exhibit 55: AstraZeneca Plc - Organizational developments
Exhibit 56: AstraZeneca Plc - Geographic focus
Exhibit 57: AstraZeneca Plc - Key offerings
Exhibit 58: AstraZeneca Plc - Key customers
Exhibit 59: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 60: F. Hoffmann-La Roche Ltd. - Product segments
Exhibit 61: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 62: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 63: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 64: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 65: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 66: Merck & Co. Inc. - Vendor overview
Exhibit 67: Merck & Co. Inc. - Business segments
Exhibit 68: Merck & Co. Inc. - Organizational developments
Exhibit 69: Merck & Co. Inc. - Geographic focus
Exhibit 70: Merck & Co. Inc. - Segment focus
Exhibit 71: Merck & Co. Inc. - Key offerings
Exhibit 72: Merck & Co. Inc. - Key customers
Exhibit 73: Mylan NV - Vendor overview
Exhibit 74: Mylan NV - Product segments
Exhibit 75: Mylan NV - Organizational developments
Exhibit 76: Mylan NV - Geographic focus
Exhibit 77: Mylan NV - Segment focus
Exhibit 78: Mylan NV - Key offerings
Exhibit 79: Mylan NV - Key customers
Exhibit 80: Pfizer Inc. - Vendor overview
Exhibit 81: Pfizer Inc. - Business segments
Exhibit 82: Pfizer Inc. - Organizational developments
Exhibit 83: Pfizer Inc. - Geographic focus
Exhibit 84: Pfizer Inc. - Segment focus
Exhibit 85: Pfizer Inc. - Key offerings
Exhibit 86: Pfizer Inc. - Key customers
Exhibit 87: Validation techniques employed for market sizing
Exhibit 88: Definition of market positioning of vendors